Table 3.
Adverse effects of alfuzosin, tamsulosin and silodosin compared with placebo.
| Adverse effect | Drug | Placebo | |
|---|---|---|---|
| Tamsulosina | Dizziness, % | 14.9 | 10.1 |
| Abnormal ejaculation, % | 8.4 | 0.2 | |
| Asthenia/fatigue, % | 7.8 | 5.5 | |
| Libido decreased, % | 1.0 | 1.2 | |
| Amblyopia, % | 0.2 | 0.4 | |
| Alfuzosinb | Upper respiratory tract infection, % | 3.0 | 0.6 |
| Dizziness, % | 5.7 | 2.8 | |
| Headache, % | 3.0 | 1.8 | |
| Fatigue, % | 2.7 | 1.8 | |
| Silodosinc | Retrograde ejaculation, % range | 14.2–28.1 | 0–1.1 |
| Thirst, % | 10.3 | 4.5 | |
| Loose stool, % | 9.1 | 5.6 | |
| Dizziness, % range | 3.2–5.1 | 4.5 | |
| Orthostatic hypotension, % | 2.6 | 1.5 | |
| Headache, % range | 2.4–5.5 | 0.9–4.7 | |
| Ejaculatory disorders leading to discontinuation of the study, % range | 1.3–2.9 | 0 |
a
Tamsulosin [package insert] Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, 2003.
b
Alfuzosin [package insert] Bridgewater, NJ: Sanofi-Synthelabo, Inc, 2004.
c
Cho HJ and Yoo TK. Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability. Res Rep Urol 2014; 6: 113–119.